News ArchivesRead News

MSU researchers identify path to treat Parkinson’s disease at its inception

Tuesday January 17, 2012

Yujie Chen, MSU graduate student, was one of the co-authors of the paper

Michigan State University - Imagine if doctors could spot Parkinson’s disease at its inception and treat the protein that triggers it before the disease can sicken the patient.

A team of researchers led by Basir Ahmad, a postdoctoral researcher at Michigan State University, has demonstrated that slow-wriggling alpha-synuclein proteins are the cause of aggregation, or clumping together, which is the first step of Parkinson’s. The results are published in the current issue of the Proceedings of the National Academy of Sciences.

Proteins, which are chain molecules composed of amino acids, do most of the work in cells. While scientists understand how proteins are structured, they do not yet know how they are built – a process known as folding. When errors happen in folding, proteins clump together, form plaques such as those found in Parkinson’s disease, Alzheimer’s and Lou Gehrig’s disease, and cause cells to degenerate.

Lisa Lapidus, MSU associate professor of physics and astronomy and co-author of the paper, has dedicated her lab to researching folding. Using lasers to investigate the protein alpha-synuclein, the scientists correlated the speed at which the protein rearranges with its tendency to clump. A slower speed places the protein in a “dangerous regime,” a pace that allows it to develop sticky patches, aggregate and cause cellular damage, Lapidus said.

“There are many, many steps that take place in aggregation, but we’ve identified the first step,” she said. “Finding a method to fight the disease at its first stage, rather than somewhere further down the road, can hopefully increase the success rate in which the disease is treated.”

The identification of this critical first step already has the researchers pursuing new ways to attack the disease. Lapidus is currently testing a number of naturally occurring compounds, such as curcumin, ECGC and resveratrol, which could push the rearranging protein out of the danger zone.

“We are now looking for molecules that can alter the protein when it first begins to ‘misfold,’ which could eventually lead to the development of a drug that could prevent aggregation before it happens,” she said.


Recent News

Oct 2 - A New Attack on Parkinson's Disease
Oct 2 - Antipsychotics for Parkinson's Psychosis May Be Dangerous
Sep 27 - The beginning of the end? The race for a Parkinson’s cure
Sep 23 - Scientists map Parkinson's spread in brain
Sep 22 - Understanding Parkinson's Disease: An Interview with Jon Palfreman
Sep 22 - Living with Lewy Body Dementia
Sep 21 - Adults with autism likely to develop Parkinson’s disease, says study
Sep 16 - Everyday activity more beneficial than occasional strenuous exercise for Parkinson’s disease
Sep 14 - UNC scientists create smarter immune cells to treat Parkinson's disease
Sep 9 - A newly discovered brain disease may point to something disturbing about Alzheimer’s and Parkinson’s
Sep 7 - Treatment for Parkinson's could replace surgery
Sep 4 - Asthma May Influence Risk of Parkinson's Disease
Sep 4 - Researchers Explore Memory Problems Related to Parkinson's
Sep 3 - Press Release: ACADIA Pharmaceuticals Submits New Drug Application for NUPLAZID™ for the Treatment of Parkinson’s Disease Psychosis
Aug 28 - Brain cells 'burn out' in Parkinson's disease
Aug 24 - Study Details Process Involved in Parkinson’s Disease
Aug 24 - Google Reveals Gigantic Ambitions To Fight Cancer, Diabetes, Parkinson's, Heart Problems
Aug 20 - Two proteins work together to help cells eliminate trash; Parkinson's may result
Aug 17 - Scientists visualize critical part of basal ganglia pathways
Aug 17 - VA benefits office seeks all vets exposed to Agent Orange